Artificial intelligence in automatic image segmentation system for exploring recurrence patterns in small cell carcinoma of the lung.

Background: The integration of artificial intelligence (AI) in automatic image segmentation systems offers a novel approach to evaluating the clinical target volume (CTV) in small cell lung cancer (SCLC) patients. Utilizing imaging recurrence data, this study applies a recursive feature elimination algorithm to model and predict patient prognoses, aiming to enhance clinical guidance and prediction accuracy.

Materials And Methods: This research analyzed data from SCLC patients who received curative radiotherapy from January 1, 2010, to December 30, 2021, and had comprehensive follow-up records including pre- and post-treatment imaging.

Clinical target volume automatic segmentation based on lymph node stations for lung cancer with bulky lump lymph nodes.

Background: The lack of standardized delineation of lymph node station in lung cancer radiotherapy leads to nonstandard clinical target volume (CTV) contouring, especially in patients with bulky lump gross target volume lymph nodes (GTVnd). This study defines lymph node region boundaries in radiotherapy for lung cancer and automatically contours lymph node stations based on the International Association for the Study of Lung Cancer (IASLC) lymph node map.

Methods: Computed tomography (CT) scans of 200 patients with small cell lung cancer were collected.

Management of immune checkpoint inhibitor-related adverse events: A review of case reports.

Immune checkpoint inhibitors represent a major breakthrough in cancer therapy. Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action. Management of irAEs is based on clinical experience because it is not easy to conduct prospective trials to evaluate the best treatment strategy.

[Analysis of Small Cell Lung Cancer with Paraneoplastic Limbic Encephalitis].

Background: The aim of this study was to investigate the clinical features of paraneoplastic limbic encephalitis (PLE) with small cell lung cancer (SCLC) and improve clinical diagnosis and treatment.

Methods: The clinical data of 15 patients with SCLC combined with PLE from January 1980 to May 2017 were collected from Beijing Union Hospital. Their symptoms and laboratory data were analyzed and the prognosis of the patients was followed.

Pembrolizumab for non-small cell lung cancer with central nervous system metastases: A two-case report.

Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. Central nervous system metastases are a common complication of NSCLC and confer a poor prognosis and a dismal survival rate. Treatment is limited, has poor outcomes, and affects patient quality of life.